U.S. markets open in 4 hours 46 minutes
  • S&P Futures

    3,801.50
    -37.50 (-0.98%)
     
  • Dow Futures

    31,333.00
    -132.00 (-0.42%)
     
  • Nasdaq Futures

    12,401.00
    -262.75 (-2.07%)
     
  • Russell 2000 Futures

    2,165.80
    -23.90 (-1.09%)
     
  • Crude Oil

    66.30
    +0.21 (+0.32%)
     
  • Gold

    1,686.90
    -11.60 (-0.68%)
     
  • Silver

    25.26
    -0.02 (-0.09%)
     
  • EUR/USD

    1.1875
    -0.0050 (-0.42%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    28.30
    -0.27 (-0.95%)
     
  • GBP/USD

    1.3825
    -0.0003 (-0.02%)
     
  • USD/JPY

    108.5400
    +0.1580 (+0.15%)
     
  • BTC-USD

    49,730.00
    -817.27 (-1.62%)
     
  • CMC Crypto 200

    1,004.25
    +61.08 (+6.48%)
     
  • FTSE 100

    6,619.86
    -10.66 (-0.16%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

AstraZeneca working on vaccine with Oxford to target new variant, CEO says -La Repubblica

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Jan 26 (Reuters) - AstraZeneca Chief Executive Pascal Soriot said on Tuesday that the British drugmaker is working with Oxford University on a vaccine that will target the South African variant of COVID-19.

"Having said that, we're also working on a vaccine with Oxford University that will target the variant," Soriot told Italian daily La Repubblica in an interview https://bit.ly/2KWidAc published late on Tuesday.

(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie Adler)